OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

Research News

OCRF Research Finds Inherited Mutations in 18% with Ovarian Cancer

Barbara Norquist, MD Elizabeth Swisher, MD (Jan. 8, 2016) OCRF grantees Dr. Barbara Norquist and Dr. Elizabeth Swisher were part of a team that recently released a study which investigated the occurrence, and role of, inherited cancer associated genes in a randomly selected population of women diagnosed... 

Study Results Show Ovarian Cancer Screening Doesn’t Save Lives; Researchers Optimistic About Future Results

(December 17, 2015) This morning in London, researchers announced the long-awaited final results of the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The trial showed that average-risk, post-menopausal women who were screened for ovarian cancer based on a test called ROCA... 

Nintedanib Delays Progression of Advanced Ovarian Cancer

(December 4, 2015) According to the results of a phase III trial of over 1,000 women, women with advanced ovarian cancer gained significant delays in the progression of their disease when they were treated with the drug nintedanib plus carboplatin/paclitaxel, compared with women treated with carboplatin/paclitaxel... 

OCRF Research Identifies Targetable Mutations in Low Grade Serous Ovarian Cancer

(December 2, 2015) Research funded in part by an OCRF grant to Rachel Grisham, MD has identified new, potentially targetable mutations in patients with low grade serous ovarian cancer. Dr. Grisham is a medical oncologist at Memorial Sloan Kettering Cancer Center in New York and is a 2014 recipient of... 

OCRF Research Offers Insight on How Ovarian Cancer Grows

Ron Buckanovich, MD, PhD (December 1, 2015) Research funded in part by Ovarian Cancer Research Fund, and published in PNAS, offers new insights into how ovarian cancer grows—and the potential to stop it. Can any cancer cell form another tumor, or is it only select cancer stem cells that give rise to... 

Better Outcomes for Ovarian Cancer Patients with History of Oral Contraceptive Use

(November 20, 2015) A study published in BMC Cancer demonstrates that ovarian cancer patients who had a history of oral contraceptive use had better outcomes than those who had not previously used them. Dr. Aminah Jatoi and co-author Dr. Ellen Goode, both of the Mayo Clinic, examined 1,398 cases during... 

Ten-year Survival Not Associated with BRCA Mutation Status

(Nov. 19, 2016) In research published this month in Gynecologic Oncology, a group of Canadian researchers have found that long-term survival is not associated with BRCA mutation status in ovarian cancer patients. Past research has shown that after a diagnosis of ovarian cancer, positive BRCA mutation... 

Meet OCRF’s 2016 Grantees

(Nov. 17, 2015) Ovarian Cancer Research Fund has announced that $5.2 million has been awarded in scientific research grants for ovarian cancer. This brings OCRF’s total investment in research to nearly $70 million. OCRF’s 2016 grants have been awarded to eighteen top scientists at thirteen leading... 

OCRF Research Explains Limits of Cancer Immunotherapy Drugs

Weiping Zou, MD, PhD A new study of ovarian cancer cells from the University of Michigan Comprehensive Cancer Center, funded in part by an OCRF grant to Dr. Weiping Zou, reveals molecular changes within the tumor that prevent immunotherapy drugs from killing off the cancer.  The research was published... 

BRCA Mutations Confer Risk, Even in Absence of Family History

(October 15, 2015)  According to a Japanese study published in Cancer, BRCA1/2 gene mutations may be associated with an inherited risk of ovarian cancer regardless of family history. The researchers examined 95 women with ovarian cancer who were treated from 2013 to 2015.  BRCA1/2 gene mutation...